Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prabhavathi Fernandes

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Expert Opinion on Drug Discovery|March 15, 2013
Biotechnology financing, not acquisitions, for filling the pharma pipeline - a sustaining strategyPrabhavathi Fernandes
The Journal of Antibiotics|August 31, 2023
Antibiotic stewardship programs should include disinfectants and biocidesPrabhavathi Fernandes
The Journal of Infectious Diseases|September 18, 2024
Will mortality rates in the next viral pandemic be affected by the COVID-19 experience?Prabhavathi Fernandes
Nature Biotechnology|October 15, 2011
Headwinds into opportunityPrabhavathi Fernandes
Current Opinion in Pharmacology|June 30, 2015
The global challenge of new classes of antibacterial agents: an industry perspectivePrabhavathi Fernandes
Nature Biotechnology|December 13, 2006
Antibacterial discovery and development--the failure of success?Prabhavathi Fernandes
Cold Spring Harbor Perspectives in Medicine|January 6, 2016
Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal InfectionsPrabhavathi Fernandes
The Lancet. Infectious Diseases|March 27, 2015
Investment in antibiotics against pneumoniaPrabhavathi Fernandes
Current Opinion in Microbiology|September 23, 2008
Addressing the frustrations of finding new effective antibacterials to combat drug resistant bacteriaPrabhavathi Fernandes, Mariagrazia Pizza
Bioorganic & Medicinal Chemistry Letters|November 19, 2010
Synthesis and antibacterial activity of novel 4-aryl-[1,2,3]-triazole containing macrolidesDavid Pereira, Prabhavathi Fernandes
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Expert Opinion on Drug Discovery|March 15, 2013
Biotechnology financing, not acquisitions, for filling the pharma pipeline - a sustaining strategyPrabhavathi Fernandes
The Journal of Antibiotics|August 31, 2023
Antibiotic stewardship programs should include disinfectants and biocidesPrabhavathi Fernandes
The Journal of Infectious Diseases|September 18, 2024
Will mortality rates in the next viral pandemic be affected by the COVID-19 experience?Prabhavathi Fernandes
Nature Biotechnology|October 15, 2011
Headwinds into opportunityPrabhavathi Fernandes
Current Opinion in Pharmacology|June 30, 2015
The global challenge of new classes of antibacterial agents: an industry perspectivePrabhavathi Fernandes
Nature Biotechnology|December 13, 2006
Antibacterial discovery and development--the failure of success?Prabhavathi Fernandes
Cold Spring Harbor Perspectives in Medicine|January 6, 2016
Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal InfectionsPrabhavathi Fernandes
The Lancet. Infectious Diseases|March 27, 2015
Investment in antibiotics against pneumoniaPrabhavathi Fernandes
Current Opinion in Microbiology|September 23, 2008
Addressing the frustrations of finding new effective antibacterials to combat drug resistant bacteriaPrabhavathi Fernandes, Mariagrazia Pizza
Bioorganic & Medicinal Chemistry Letters|November 19, 2010
Synthesis and antibacterial activity of novel 4-aryl-[1,2,3]-triazole containing macrolidesDavid Pereira, Prabhavathi Fernandes
Pageof 6